Radioimmunotherapy of Colorectal Cancer in Mice
Author Information
Author(s): P Antoniwl, APH Farnsworth, A Turner, AMR Haines, A Mountain, J Mackintosh, D Shochat, J Humm, S Welt, LJ Old, GT Yarranton, DJ King
Primary Institution: Celltech Therapeutics Ltd.
Hypothesis
Can yttrium-90 labelled A33 IgG and Tri-Fab (TFM) effectively treat colorectal carcinoma xenografts in nude mice?
Conclusion
Both A33 IgG and TFM showed potent anti-tumour effects, with TFM demonstrating reduced toxicity and faster tumour penetration.
Supporting Evidence
- A33 IgG localized to tumours with a maximum of 35.9% injected dose per gram.
- TFM showed faster blood clearance and lower toxicity compared to IgG.
- Both treatments resulted in complete regression of tumours in some mice.
- TFM had better tumour-blood ratios at 48 hours post-administration.
- Significant drops in white blood cell counts were observed with both treatments.
Takeaway
This study tested a special treatment for colon cancer in mice using a targeted approach with antibodies, showing that one method worked better and was safer than the other.
Methodology
Mice with colon cancer xenografts were treated with either A33 IgG or TFM, and their tumour response and blood cell counts were monitored.
Potential Biases
Potential bias in the selection of treatment dosages and animal models.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
Nude mice bearing SW1222 colon carcinoma xenografts.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website